Dengvaxia US Pregnancy Registry
ConditionDengue Virus Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSanofi Pasteur, a Sanofi Company
About this trial
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
Eligibility criteria
Qualifiers
Sufficient evidence to confirm the case qualifies as "exposed during pregnancy";
Vaccine name (brand or generic) is provided (i.e., including manufacturer unknown exposures).
Disqualifiers
None
Trial design
Treatments tested in this trial
- Dengue Tetravalent Vaccine, Live
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov